Cefamandole: In Vitro and Clinical Pharmacokinetics

AUTOR(ES)

Griffith, R. S.

RESUMO

Cefamandole has a broader spectrum and greater potency than the other cephalosporins. It includes Haemophilus influenzae, most strains of Enterobacter, and many strains of indole-positive Proteus and Bacteroides, with a lower minimal inhibitory concentration for Escherichia coli, Klebsiella, etc. Concentrations of drug in the serum after the parenteral injection of cefamandole exceed manyfold the minimal inhibitory concentrations of over 82% of the bacteria studied. Approximately 65 to 85% is excreted in a biologically active form in the urine. This antibiotic offers advantages of antibacterial effectiveness and at the same time retains the safety of penicillin G and cephalothin in animals.

Documentos Relacionados

• Cefamandole: Antimicrobial Activity In Vitro of a New Cephalosporin
• In Vitro Activity and Pharmacokinetics in Patients of Cefamandole, a New Cephalosporin Antibiotic
• Clinical Pharmacokinetics of Cefamandole and Ceftazidime Administered by Continuous Intravenous Infusion
• Pharmacokinetics of Cefamandole in Infants and Children
• Emergence of Resistance to Cefamandole: Possible Role of Cefoxitin-Inducible Beta-Lactamases